| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 42.90 | 8.9% | 2.5% |
| Total Income | 42.90 | 8.9% | 2.5% |
| Expenditure | 42.93 | 4.2% | 0.7% |
| PBT | -1.21 | 57.7% | 55.1% |
| Net Profit | -1.11 | 53.8% | 88.1% |
| OPM | -0.07% | 4.51pp | 1.85pp |
| NPM | -2.59% | 3.49pp | 1.25pp |
| EPS | -0.02 | 33.3% | 100.0% |
AirSculpt Technologies Reports Q2 2026 Results
10 Aug 2026 · 10 Aug, 3:45 pm
Summary
AirSculpt Technologies reported second quarter 2026 results with a 3% decline in revenue to $42.9 million and a net loss of $1.1 million. While same center case volume saw a 1.0% increase, Adjusted EBITDA decreased to $4.9 million. The company reaffirmed its full-year revenue guidance at the lower end of its range but reduced its full-year Adjusted EBITDA outlook. Management highlighted advancements in key priorities, including a new partnership with AlloClae to expand treatment offerings and increased marketing investment.
Key Highlights
- 1
Same center case volume grew 1.0% in Q2 2026 compared to the prior year.
- 2
Revenue for the second quarter of 2026 declined 3% to $42.9 million from $44.0 million in the fiscal year 2025.
- 3
The company reported a net loss of $1.1 million for the second quarter of 2026, compared to a net loss of $0.6 million in the fiscal year 2025 second quarter.
- 4
Adjusted EBITDA for the second quarter of 2026 was $4.9 million, down from $5.8 million in the fiscal year 2025 second quarter.
- 5
The company reaffirmed its full year 2026 revenue guidance at the lower end of its range of approximately $151 to $157 million.
- 6
Full year 2026 adjusted EBITDA outlook was reduced to the range of approximately $12 to $14 million.
- 7
Gross debt was reduced by approximately $30 million to $44.2 million, and cash increased by approximately $10 million to $18.8 million.
Management Comments
Yogi Jashnani
In the second quarter, we advanced our key priorities — delivering our second quarter of stability. During the quarter, we stepped up our investment in marketing and advanced our plans to introduce new, sought-after procedures including entering an exclusive partnership with AlloClae that expands our treatment offering and enhances our body contouring platform. We enter the second half of the year a fundamentally stronger company with the right strategy and team. Our addressable market is larger, our procedure mix is broader, and our operating platform is more disciplined than it was twelve months ago.
Informational and educational content only. Not investment advice.